Models of GLP-1 RAs were most sensitive to the effects of GLP-1 RAs on all-cause mortality, with the ICERs varying from AU$72,318 to AU$172,072 per QALY in the total population and AU$58,588 to AU$142,317 in the secondary prevention population for the lower and upper bounds of the 95% CI of the HR for GLP-1 RAs
Lilly, the drugs manufacturer, said it would offer a savings card for patients with commercial insurance to get the drug for $25 for a one or three-month supply, if the patients insurance plan covers the medication
Knowing whats causing your symptoms
Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease
You have a contraindicated endocrine history: If you or a close family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), tirzepatide is contraindicated
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management, requires specific storage conditions to maintain its stability and therapeutic efficacy
